Asthma is a multifaceted disease with numerous symptoms and endotypes. Unmet needs in severe asthma have resulted in the discovery of prospective treatment targets that go beyond present medications. Several biologics have recently been studied, and some have now been licenced to treat T2 airway inflammation in patients with severe illness. The study presents an overview of newly authorised biologics, emerging biologics, and unmet needs in this field. Multiple biologics targeting T2 high asthma are now available for clinical usage in severe asthma patients. These drugs target overlapping characteristics such as allergic and eosinophilic asthma.

Available biologics have been found to improve outcomes such as exacerbation reduction and lung function improvement. Some studies have also shown an improvement in patient-reported outcomes. Some of these biologics have also been shown to improve asthma-related comorbidities. Although just a few biomarkers are now available, they help predict response to some biologics. Emerging biologics are being developed to target various mechanisms of airway inflammation. A number of small molecule antagonists and inhibitors are also in the works. There is a need for biologics and medicines that target T2 low or non-T2 asthma. Biologic medicines that have recently been licenced enhance asthma outcomes in a group of patients. Future study to identify better predictors of response can help enhance the precise approach to therapy for people with severe disease.